The HCPLive Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.
March 18th 2024
In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.
Community Practice Connections™: Preparing for an Expanded Armamentarium for Food Allergy
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
OUtMATCH: Omalizumab Proves Utility in Multiple Food Allergies for Pediatric, Adult Patients
February 25th 2024Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.
FDA Approves Omalizumab as First Treatment of 1 or More Food Allergies for Children, Adults
The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.
All Doses of Birch Pollen Allergoids Shown to be Safe for Allergic Rhinoconjunctivitis
This represented the first in human research focused on assessing the best dosing regimen of mannan-conjugated birch pollen allergoids for those with birch pollen–induced allergic rhinoconjunctivitis.
Dupilumab Prescriptions for Pediatric EoE Burdened by Prior Authorizations, Delayed Initiation
October 5th 2023An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.
Where There is Smoke: Wildfire Preparedness as a Health Care Provider
Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.
Hospitalizations Associated with Rotavirus Linked to Subsequent Autoimmune Disease in Childhood
This recent research indicates the necessity for clinicians to be aware of the higher autoimmune disease susceptibility of those with previous rotavirus-associated hospitalization.